In an analogous approach, a DNA vaccine encoding the GRP-HSP65 fusion product showed anti-tumor activities in a prophylactic setting for subcutaneous implanted tumors and a pulmonary metastasis model [116]. Here, HSPD1 is linked to neoplasm.